flurazepam
Trade name: dalmane
Approved
Apr 7, 1970
Flurazepam (known under the brand names Dalmane and Dalmadorm) is a drug which is a benzodiazepine derivative. It is a hypnotic agent which does not appear to decrease dream time as measured by rapid eye movements (REM). Furthermore, it decreases sleep latency and number of awakenings for a consequent increase in total sleep time. Flurazepam binds to an allosteric site on GABA-A receptors. Binding potentiates the action of GABA on GABA-A receptors by opening the chloride channel within the receptor, causing chloride influx and hyperpolarization. Flurazepam is useful for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakening. Flurazepam can be used effectively in patients with recurring insomnia or poor sleeping habits, and in acute or chronic medical situations requiring restful sleep. — NCATS
Clinical trial activity
2 trials · 2 clinical orgs · 18 marketing orgs
Earliest trial started Jan 1, 2015 (NCT02350309)
Timeline
1970s
- Apr 7, 1970
Roche — Earliest FDA Approval
- Apr 7, 1970
Bausch Health Companies — NDA Secondary Org
- Apr 7, 1970
Roche — NDA Organization
1980s
- Jun 12, 1985
Mylan — Marketing Organization
- Mar 20, 1986
Par Pharmaceuticals — Marketing Organization
- Mar 20, 1986
Strides Pharma Science — Marketing Organization
- Mar 20, 1986
Novitium Pharma — Marketing Organization
- Aug 4, 1986
Sun Pharmaceuticals — Marketing Organization
- Nov 25, 1986
Watson Pharmaceuticals — Marketing Organization
- Nov 25, 1986
Heritage Pharma — Marketing Organization
- Nov 25, 1986
Chartwell Pharmaceuticals — Marketing Organization
- Dec 8, 1986
Hikma — Marketing Organization
- Jul 9, 1987
Upsher-Smith Laboratories — Marketing Organization
- Jan 7, 1988
Halsey — Marketing Organization
- Aug 4, 1988
Superpharm — Marketing Organization
1990s
- Jul 31, 1991
Rising Pharmaceuticals — Marketing Organization
- Jul 31, 1991
Aurobindo Pharma — Marketing Organization
Indications
Mechanism of action
- GABA-A receptor; anion channelPOSITIVE ALLOSTERIC MODULATOR
GABA-A receptor; anion channel positive allosteric modulator
Benzodiazepine site
- Gamma-aminobutyric acid receptor subunit alpha-1 (GABRA1) ↗
- Gamma-aminobutyric acid receptor subunit beta-2 (GABRB2) ↗
- Gamma-aminobutyric acid receptor subunit gamma-2 (GABRG2) ↗
- Gamma-aminobutyric acid receptor subunit beta-3 (GABRB3) ↗
- Gamma-aminobutyric acid receptor subunit alpha-4 (GABRA4) ↗
- Gamma-aminobutyric acid receptor subunit gamma-3 (GABRG3) ↗
- Gamma-aminobutyric acid receptor subunit theta (GABRQ) ↗
- Gamma-aminobutyric acid receptor subunit alpha-3 (GABRA3) ↗
- Gamma-aminobutyric acid receptor subunit pi (GABRP) ↗
- Gamma-aminobutyric acid receptor subunit delta (GABRD) ↗
- Gamma-aminobutyric acid receptor subunit gamma-1 (GABRG1) ↗
- Gamma-aminobutyric acid receptor subunit beta-1 (GABRB1) ↗
- Gamma-aminobutyric acid receptor subunit epsilon (GABRE) ↗
- Gamma-aminobutyric acid receptor subunit alpha-2 (GABRA2) ↗
- Gamma-aminobutyric acid receptor subunit alpha-5 (GABRA5) ↗
- Gamma-aminobutyric acid receptor subunit alpha-6 (GABRA6) ↗
- GABA receptor alpha-1 subunit
- GABA receptor beta-2 subunit
- GABA receptor alpha-4 subunit
- GABA receptor delta subunit
- GABA receptor alpha-5 subunit
- GABA receptor alpha-6 subunit
- GABA receptor beta-3 subunit
- GABA receptor alpha-3 subunit
- GABA receptor alpha-2 subunit
- GABA-A receptor; GABA-A site (alpha1/beta2 interface)
- GABA-A receptor; alpha-3/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-3/gamma-2
- GABA-A receptor; alpha-5/beta-3/gamma-2
- GABA-A receptor; alpha-2/beta-3/gamma-2
- GABA-A receptor; alpha-1/beta-2/gamma-2
- GABA-A receptor; alpha-6/beta-3/gamma-2
- GABA-A receptor; benzodiazepine site
- GABA-A receptor; agonist GABA site
- GABA A receptor alpha-2/beta-2/gamma-2
- GABA A receptor alpha-3/beta-2/gamma-2
- GABA A receptor alpha-6/beta-2/gamma-2
- GABA A receptor alpha-1/beta-1/gamma-2
- GABA A receptor alpha-4/beta-3/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta3/delta
- Gamma-aminobutyric acid receptor subunit alpha-1/ beta-1
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-2
- Gamma-aminobutyric acid receptor subunit alpha-3/ beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-3/beta-3/theta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3/gamma-3
- Gamma-aminobutyric acid receptor subunit alpha-6/beta-3
- GABA-A receptor alpha-1/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/beta-2/delta
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/delta
- Gamma-aminobutyric acid receptor subunit beta-1/beta-2
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-3
- Gamma-aminobutyric acid receptor subunit alpha-1/alpha-2/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-1/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-2/gamma-2
- Gamma-aminobutyric acid receptor subunit alpha-4/beta-1/delta
- Gamma-aminobutyric acid receptor subunit alpha-5/beta-2/gamma-2
- GABA receptor beta-1 subunit
- Gamma-aminobutyric acid receptor subunit alpha-2/beta-1/gamma-2
Approval history
- approvedPriority reviewApr 7, 1970
Chemistry & pharmacology
SMILES
CCN(CC)CCN1C(=O)CN=C(c2ccccc2F)c2cc(Cl)ccc21.Cl.Cl- Mol. weight
- 460.81 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3989724 ↗
- WikipediaFlurazepam ↗
- NCATSIHP475989U ↗
- ChEMBLCHEMBL968 ↗
- ChEMBLCHEMBL1200602 ↗
Also known as
- dalmane
- dalmane
- dalmane
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazepam
- flurazépam
- flurazépam
- flurazepam hcl
- flurazepam hcl
- flurazepam hcl
- flurazepam hydrochloride
- flurazepam hydrochloride
- flurazepam hydrochloride
- flurazepam hydrochloride
- flurazepamum
- flurazepamum
- insumin
- insumin
- ro-56901
- ro-56901
- ro-5-6901
- ro-5-6901
- stauroderm
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02350309 | Phase 1 | Jan 1, 2015 | Eisai |
| NCT02374567 | Phase 3 | Jan 1, 2015 | Gottfried Wilhelm Leibniz Universität Hannover |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eisai | For profit | 1 | 1 | 1 | 2015 |
| Gottfried Wilhelm Leibniz Universität Hannover | Academic/Hospital | 1 | 1 | 1 | 2015 |
Marketing (20)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Aurobindo Pharma | For profit | MKTG | Jul 31, 1991 |
| Bausch Health Companies | For profit | NDA2 | Apr 7, 1970 |
| Chartwell Pharmaceuticals | For profit | MKTG | Nov 25, 1986 |
| Halsey | For profit | MKTG | Jan 7, 1988 |
| Heritage Pharma | For profit | MKTG | Nov 25, 1986 |
| Hikma | For profit | MKTG | Dec 8, 1986 |
| Hikma | For profit | SYN | Dec 8, 1986 |
| Hikma | For profit | SYN | Dec 8, 1986 |
| Mylan | For profit | MKTG | Jun 12, 1985 |
| Novitium Pharma | For profit | MKTG | Mar 20, 1986 |
| Par Pharmaceuticals | For profit | MKTG | Mar 20, 1986 |
| Puracap Pharmaceutical | For profit | MKTG | — |
| Rising Pharmaceuticals | For profit | MKTG | Jul 31, 1991 |
| Roche | For profit | NDA | Apr 7, 1970 |
| Strides Pharma Science | For profit | MKTG | Mar 20, 1986 |
| Sun Pharmaceuticals | For profit | MKTG | Aug 4, 1986 |
| Superpharm | For profit | MKTG | Aug 4, 1988 |
| Upsher-Smith Laboratories | For profit | MKTG | Jul 9, 1987 |
| Warner Chilcott | For profit | MKTG | — |
| Watson Pharmaceuticals | For profit | MKTG | Nov 25, 1986 |